Micro-elimination of hepatitis C virus (HCV) infection through rapid uptake of government-funded direct-acting antiviral therapy within an Australian prison setting is demonstrated. During a 22-month period, 119 patients initiated treatment for chronic HCV infection, with HCV in-prison viremic prevalence declining from 12% to 1%.
Micro-elimination of hepatitis C virus (HCV) infection from defined populations has been proposed as a strategy [1] to assist the World Health Organization goals for elimination of HCV as a public health threat by 2030 [2] . HCV is highly prevalent among incarcerated populations, with global prevalence over 10% [3] , and considerably higher among people who inject drugs (PWID) who are incarcerated [4, 5] . Globally, more than 10 million people are incarcerated on a daily basis [6] , with many more annually, making prisons a key setting for implementation of HCV elimination strategies.
Unrestricted access through the Australian Pharmaceutical Benefits Scheme to direct-acting antiviral (DAA) therapy for chronic HCV infection began in March 2016, including provision for people in the correctional system. This has provided the opportunity to evaluate rapid DAA therapy scale-up and its impact on HCV incidence and prevalence in Australian correctional centres.
Lotus Glen Correctional Centre (LGCC), located near Cairns in Queensland, Australia, is a high security correctional facility with 800 beds, accommodating both sentenced and unsentenced (on remand) men. A program of rapid DAA-based HCV treatment scale-up was initiated in LGCC in March 2016. We describe DAA therapy uptake and outcomes, including in-prison HCV viremic prevalence trend after 22 months of the treatment program.
METHODS
All entrants to LGCC are offered routine voluntary bloodborne virus and sexually transmitted infection screening at reception, with those testing positive for HCV antibody (Ab) referred to LGCC nursing staff for confirmatory HCV RNA and HCV genotype testing. People detained in LGCC also undergo HCV testing upon self-identification of possible HCV exposure or symptomatic presentation to LGCC nursing staff. During visits to LGCC by an external team consisting of a hepatology nurse (fortnightly visits) and sexual health physician (monthly visits), those with detectable HCV RNA underwent liver disease evaluation (hepatic elastography via Fibroscan ® or AST to platelet ratio index) and were prescribed an interferon-free DAA regimen for 8, 12, or 24 weeks. Patients received directly observed DAA therapy and received counseling and education on prevention of HCV reinfection. Linkage to care in the community upon release to freedom was provided through public hospitals and sexual health clinics.
HCV treatment outcome was sustained virological response 12 (SVR12), defined as having an undetectable HCV RNA test at least 12 weeks after completion of treatment, assessed in intention to treat and per protocol (PP) populations. HCV viremic point prevalence was defined as the estimated proportion of people with detectable HCV RNA within the facility, prior to commencement of the DAA program (February 29, 2016) , at 12 months (March 1, 2017), and 22 months (December 31, 2017) following commencement. In estimating HCV point prevalence, both patients with undetectable HCV RNA test results, and patients on-treatment with 4 or more weeks of therapy were considered to have undetectable HCV [7, 8] . 
B R I E F R E P O R T
In total, 125 patients were assessed for HCV treatment at LGCC from March 1, 2016, to December 31, 2017. Four patients refused treatment, and 2 were transferred to another correctional facility prior to initiating treatment. All 119 patients initiating treatment were male, median age was 34 years, and 12% (n = 14) had cirrhosis. The most common genotype was 3a (61%; n = 72), and the most commonly prescribed regimen was sofosbuvir plus daclatasvir for 12 weeks (41%, n = 49) ( Table 1 and Supplementary Figure 1) .
Among the 119 patients, at the end of the study period, 12 remained on-treatment, and 9 were in post-treatment follow-up prior to SVR12. Of 98 remaining patients with potentially evaluable outcomes, 32 were lost to follow-up, including 22 released to freedom, 5 transferred to another correctional facility, and 5 remaining in LGCC. Thus, 66 patients had evaluable treatment outcomes (PP population), with 64 (97%) achieving SVR12. Two patients with HCV genotype 3a had virological relapse, confirmed by detectable HCV RNA at SVR12 and no reported exposure risk. Six HCV reinfection cases were documented, Table 1 Total n (%) (n = 119) (n = 64) (n = 2) (n = 32) (n = 12) (n = 9) Abbreviations: DAA, direct-acting antiviral; Dac, daclatasvir; Das, dasabuvir; Elb, elbasvir; Graz, grazoprevir; HCV, hepatitis C virus; IFN, interferon; Led, ledipasvir; LGCC, Lotus Glen Correctional Centre; Omb, ombitasvir; Par, paritaprevir; Q, quartile; Rbv, ribavirin; Rtv, ritonavir; Sof, sofosbuvir; SVR12, sustained virological response 12; Vel, velpatasvir. a n = 2 subjects with SVR, who remained in LGCC, had reinfection.
b n = 3 subjects with SVR, who were subsequently transferred to another facility, had reinfection.
c n = 1 subject with SVR, who was subsequently released to freedom, had reinfection.
d n = 1 subject lost to follow up was an early treatment discontinuation at 6 weeks.
confirmed by undetectable HCV RNA at SVR12 followed by subsequent detectable HCV RNA, including 2 patients in LGCC, 1 who was released to freedom, and 3 who had been transferred to another correctional centre. PP population SVR12 was 100% (28/28) for HCV genotype 1/2, and 95% (36/38) for genotype 3. Shortly prior to the DAA therapy program (January 2014-February 2016), an average of 83% of entrants received an HCV Ab test. Among those tested during this period, entry HCV viremic prevalence was 3.2% (75/2377). During the 12 months following DAA treatment introduction (March 2016-February 2017), an average of 90% of entrants per month received testing, and entrance HCV viremic prevalence was 4.0% (46/1149). In the final 10 months of the study period (March 2017-December 2017), an average of 91% of entrants per month received testing, and HCV viremic prevalence was 1.7% (18/1075). Based on number of people detained in LGCC with documented detectable HCV RNA (including diagnosed on entry or by subsequent testing), HCV viremic point prevalence in LGCC on February 29, 2016, was estimated at 12.6% (95/759). After 12 months (March 1, 2017), estimated point prevalence was 4.3% (35/815), and after 22 months (December 31, 2017), it was 1.1% (9/841). Of the 9 people in LGCC with HCV viremia at December 31, 2017, 5 had commenced treatment (but were pre-week 4), and 4 were being assessed for HCV treatment.
DISCUSSION
Micro-elimination of HCV is close to being realized in a large Australian prison, 22 months following unrestricted access to DAA therapy. DAA therapy was highly accepted among this population, with only 4 persons refusing treatment of 125 assessed. Of those receiving treatment, per protocol treatment outcome was very favourable. Two cases of HCV reinfection among persons in LGCC, and 3 cases among persons who were transferred to other correctional facilities, highlights ongoing exposure risks, the need for broadened DAA treatment scale-up, and optimized harm reduction strategies. The considerable proportion lost to follow-up highlights the complex nature of treatment delivery and post-treatment evaluation in a setting with high levels of transitioning (release to freedom and transfer to other correctional facilities) and need to improve liaison between corrections and community HCV treatment services. Of note, the LGCC DAA therapy program placed no restrictions on eligibility, based on likely incarceration period, unlike many other Australian prison settings, and was able to retain one-third of those who left LGCC in follow-up. Although two-thirds of those "lost to follow-up" related to prison transitioning, some remained in LGCC. In-prison logistic barriers, including delays experienced by nursing staff when requesting patients visit the clinic, facility lock-down days, and staff shortages, may have contributed. Nonetheless, this study demonstrates that correctional center-based DAA therapy services involving fortnightly/monthly clinics can provide favourable individual and facility population-level outcomes.
The estimated HCV viremic prevalence in LGCC declined markedly, from 12.6% to 1.1%, within a 22-month period despite continued arrival of new entrants with HCV infection. A high proportion of entrants to LGCC each month were screened for HCV Ab, with entry viremic prevalence declining over the study period. Ongoing entrance of people to LGCC with HCV infection highlights the need for continued screening, along with rapid initiation of DAA therapy, to maintain low HCV viremic prevalence. Data on HCV incidence from LGCC are not available; therefore, treatment as prevention impact is unable to be evaluated. However, marked reduction in HCV viremic prevalence should translate to a reduced risk within the prison of both initial HCV infection and post-treatment reinfection. Concurrent to HCV treatment scale-up in LGCC, a region-wide HCV elimination project also began ("Cairns Hep C Free By 2020"), which potentially enhanced treatment as prevention benefits in LGCC by reducing prevalence of HCV infection among entrants. DAA treatment scale-up was not rapidly introduced in other Queensland correctional facilities, thereby creating potential for reinfection among transferred patients.
An ongoing Australian study (SToP-C, NCT02064049) is evaluating HCV treatment as prevention in four New South Wales prisons. In this study, a 2-year HCV surveillance phase has documented HCV incidence (in the setting of standard of care HCV treatment) of 5.1/100 person years (py) [9] (13.0/100 py among those with a history of injecting drug use), and a rapid DAA therapy scale-up has recently commenced. HCV incidence prior to, during, and following DAA therapy scale-up will be compared.
The close relationship between injecting drug use, incarceration, and prevalence of blood-borne viruses makes correctional centres a crucial setting for enhanced DAA therapy access and broad prevention strategies [4] . Population-level HCV elimination success will require effective HCV treatment and prevention programs among both PWID and people who are incarcerated [10, 11] .
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